MIRA · Mira Pharmaceuticals, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“As of the date of filing this Quarterly Report on Form 10-Q, the Company has not generated revenues, continued to generate losses, and has insufficient cash and cash equivalents on hand to support its operations for at least the 12 months following the date these unaudited condensed financial statements are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Quarterly Report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail its operations. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $148.91K | $98.91K | $165.67K | — | — | |
| $2.14M | $1.72M | $3.31M | $1.57M | $2.35M | |
| $7.26M | $8.77M | $4.71M | $6.5M | $2.99M | |
| $9.4M | $10.49M | $8.02M | $8.53M | $7.05M | |
| -$136.67K | — | -$165.67K | $3.46M | $10.25K | |
| -$78.27K | $50.63K | $165.67K | — | — | |
| -$9.48M | -$10.44M | -$7.85M | -$11.98M | -$7.06M | |
| — | -$32M | -$7.85M | — | — | |
| USD/shares | -$1.21 | -$1.35 | -$0.51 | -$0.85 | -$0.40 |
| USD/shares | -$1.21 | -$1.35 | -$0.51 | -$0.85 | -$0.40 |
| shares | — | 23.69M | 15.44M | 13.92M | 17.57M |
| shares | — | — | 15.44M | 13.92M | 17.57M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2024-03-31 | USD 1,273 | 10-Q filed 2024-05-13 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.